Literature DB >> 1962094

Multidrug-resistant typhoid in children: presentation and clinical features.

Z A Bhutta1, S H Naqvi, R A Razzaq, B J Farooqui.   

Abstract

Typhoid accounts for 8% of pediatric admissions to the Aga Khan University Hospital in Karachi, Pakistan. Over a 4-year period (1986-1989), 355 children had typhoid documented by culture of blood or bone marrow. Strains of Salmonella, resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole accounted for 20% of these cases. Compared with children infected by drug-susceptible strains of Salmonella, children with multiresistant infection were generally sicker at presentation and were more likely to be assessed as appearing "toxic" (P less than .001), as having disseminated intravascular coagulation (P less than .01), and as exhibiting hepatomegaly (P less than .01). The mortality was 4.2% among children with multiresistant infection and 1.4% among those infected with strains susceptible to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; the higher mortality in the former group was probably due to a longer duration of illness (P less than .05) and to ineffectual oral antimicrobial therapy before hospitalization.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1962094     DOI: 10.1093/clinids/13.5.832

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  23 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.

Authors:  J Y Wang; M F Pasetti; F R Noriega; R J Anderson; S S Wasserman; J E Galen; M B Sztein; M M Levine
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Failure of short-course ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan.

Authors:  Z A Bhutta; I A Khan; M Shadmani
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 4.  Diagnostics for invasive Salmonella infections: Current challenges and future directions.

Authors:  Jason R Andrews; Edward T Ryan
Journal:  Vaccine       Date:  2015-04-30       Impact factor: 3.641

5.  Typhoid vaccines.

Authors:  A Aggarwal; A K Dutta
Journal:  Indian J Pediatr       Date:  2001-08       Impact factor: 1.967

6.  Impact of age and drug resistance on mortality in typhoid fever.

Authors:  Z A Bhutta
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

7.  Factors associated with encephalopathy in patients with Salmonella enterica serotype Typhi bacteremia presenting to a diarrheal hospital in Dhaka, Bangladesh.

Authors:  Daniel T Leung; Jori Bogetz; Megumi Itoh; Lakshmi Ganapathi; Mark A C Pietroni; Edward T Ryan; Mohammod Jobayer Chisti
Journal:  Am J Trop Med Hyg       Date:  2012-04       Impact factor: 2.345

8.  Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever.

Authors:  M R Wallace; A A Yousif; G A Mahroos; T Mapes; E J Threlfall; B Rowe; K C Hyams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

Review 9.  Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.

Authors:  J A Crump; P K Ram; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

10.  Multi-drug resistant typhoid fever in hospitalised children. Clinical, bacteriological and epidemiological profiles.

Authors:  R Rasaily; P Dutta; M R Saha; U Mitra; M Lahiri; S C Pal
Journal:  Eur J Epidemiol       Date:  1994-02       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.